An Open-Label Study of the Safety and Efficacy of Cidofovir for the Treatment of Relapsing Cytomegalovirus Retinitis in Patients With AIDS

Inclusion Criteria Concurrent Medication: Allowed: Antiretroviral agents. Oral trimethoprim/sulfamethoxazole. Aerosolized pentamidine. Dapsone. Fluconazole. Rifabutin. Filgrastim (G-CSF). Itraconazole. HIV vaccines. Patients must have: AIDS. CMV retinitis, with severity as specified in the Disease Status field. Life expectancy of at least 3 months. Consent of parent or guardian if less than 18 years of age. Exclusion Criteria Co-existing Condition: Patients with the following symptoms or conditions are excluded: Known clinically significant allergy to probenecid. Clinically significant cardiac disease, including symptoms of ischemia, congestive heart failure, or arrhythmia. Other active medical problems sufficient to hinder study compliance. Concurrent Medication: Excluded: Amphotericin B. Aminoglycoside antibiotics. Vidarabine. Intravenous pentamidine. CMV hyperimmune immunoglobulin. Other nephrotoxic or potentially nephrotoxic agents. Other investigational agents with anti-CMV activity. Ganciclovir. Intravenous or oral acyclovir (except following development of herpetic lesion). Foscarnet. Diuretics. Prior Medication: Excluded within 2 days prior to study entry: Ganciclovir or foscarnet. Excluded within one week prior to study entry: Amphotericin B. Aminoglycoside antibiotics. Vidarabine. Intravenous pentamidine. CMV hyperimmune immunoglobulin. Other nephrotoxic agents. Other investigational agents with anti-CMV activity. Excluded at any time: Prior systemic or intravitreal HPMPC. Drug or alcohol abuse that is considered sufficient to hinder study compliance.